Doxorubicin (generic), Adriamycin, Doxil Newswire

Doxorubicin (generic), Adriamycin, Doxil Newswire

Comprehensive Real-Time News Feed for Doxorubicin (generic), Adriamycin, Doxil.

Results 1 - 20 of 512 in Doxorubicin (generic), Adriamycin, Doxil

  1. Analyzing CytRx CorporationRead the original story w/Photo

    6 hrs ago | AmericanBankingNews.com

    CytRx Corporation and Aptose Biosciences are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends. This is a summary of recent recommendations and price targets for CytRx Corporation and Aptose Biosciences, as reported by MarketBeat.com.

    Comment?

  2. Leading Independent Proxy Advisory Firm Recommends CytRx Stockholders ...Read the original story

    Wednesday | BioSpace

    21, 2017 /PRNewswire/ -- CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced that Glass Lewis & Co.

    Comment?

  3. Researchers propose new treatment strategy for colon cancer patientsRead the original story w/Photo

    Wednesday | Medical News

    In a new study, researchers demonstrate for the first time that a previously uncharacterized protein is increased in colon cancer. The protein is immunoglobulin containing proline rich receptor-1 which was recently identified in the same laboratory as a cell adhesion molecule.

    Comment?

  4. New study offers novel treatment strategy for patients with colon cancerRead the original story w/Photo

    Wednesday | PhysOrg Weblog

    In a new study, researchers demonstrate for the first time that a previously uncharacterized protein is increased in colon cancer . The protein is immunoglobulin containing proline rich receptor-1 which was recently identified in the same laboratory as a cell adhesion molecule .

    Comment?

  5. Somewhat Favorable Press Coverage Somewhat Unlikely to Impact CytRx Corporation (CYTR) Share PriceRead the original story w/Photo

    Tuesday Sep 19 | IntersportsWire

    Headlines about CytRx Corporation have trended somewhat positive recently, Accern Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than 20 million news and blog sources.

    Comment?

  6. Abstract P527: Angiotensin-(1-7) Attenuates Doxorubicin-Induced...Read the original story

    Thursday Sep 14 | Circulation

    Doxorubicin , a commonly used and effective chemotherapeutic agent, often produces cumulative dose-dependent cardiovascular toxicity, resulting in long-term hypertrophy and fibrosis which can lead to heart failure. Adjunct therapies are thus needed to reduce Dox-induced cardiovascular toxicity and enhance long-term quality-of-life in cancer patients, especially in pediatric patients.

    Comment?

  7. Abstract P411: Angiotensin-(1-7) Preserves Mitochondrial Function in...Read the original story

    Thursday Sep 14 | Circulation

    We recently identified components of an Angiotensin- system within mitochondria of the renal cortex, as well as angiotensinogen uptake and trafficking to the Mito and nucleus in proximal tubules. Although activation of the Ang II-AT1 receptor axis is deleterious to the Mito, the functional role of Ang7 is unknown.

    Comment?

  8. New Application For AroCell Ab TK 210 Elisa Opens New Opportunities For Drug Development ResearchRead the original story

    Sunday Sep 17 | BioSpace

    AroCell AB announces today that an abstract submitted by Kiran Kumar Jagarlamudi et al entitled "Doxorubicin effects on leukemia and breast cancer cells in culture on the TK1 protein levels using AroCell TK 210 ELISA: a tool for drug development" was accepted by the Purine and Pyrimidine Society for presentation at their annual meeting in Gdansk, Poland, September 20-24, 2017. The purpose of this study was to evaluate the capacity of AroCell TK 210 ELISA to measure TK1 protein levels in cultured tumor cell lines.

    Comment?

  9. Chemotherapy Agents That Cause CardiotoxicityRead the original story w/Photo

    Friday Sep 15 | US Pharmacist

    Sonia Amin Thomas, PharmD, BCOP Assistant Professor of Pharmacy Practice Philadelphia College of Osteopathic Medicine School of Pharmacy-Georgia Campus Suwanee, Georgia ABSTRACT: Cardiotoxicity is a serious adverse effect of many conventional chemotherapy agents. There are many different types of cardiotoxicity, including reversible, irreversible, acute, chronic, and late-onset.

    Comment?

  10. Jet lag drug may aid cancer patientsRead the original story w/Photo

    Friday Sep 15 | PhysOrg Weblog

    Painful side effects from cancer medicines could be tackled with a drug that eases the effects of jet lag, research suggests. Scientists from the Universities of Edinburgh and Aberdeen focused on a common condition known as chemotherapy-induced neuropathic pain , which causes tingling and pain sensation to touch and cold temperatures that can be severe enough to cause patients to limit their chemotherapy treatment .

    Comment?

  11. Fennec Pharma Announces Preliminary Results Of SIOPEL 6 Study On...Read the original story

    Wednesday Sep 13 | BioSpace

    Fennec Pharma Announces Preliminary Results Of SIOPEL 6 Study On PEDMARK To Be Presented At The 49TH Congress Of The International Society Of Pediatric Oncology 2017 Meeting SIOPEL 6 shows that the addition of sodium thiosulfate significantly reduces the incidence of cisplatin-induced hearing loss without any evidence of tumor protection Among the first 94 evaluable patients, hearing loss occurred in 29/44=65.9% under Cisplatin Arm and in 19/50=38.0% under Cis+STS Arm, corresponding to a relative risk of 0.57 RESEARCH TRIANGLE PARK, N.C., Sept.

    Comment?

  12. Experimental technology monitors and maintains drug levels in the bodyRead the original story w/Photo

    May 12, 2017 | Medical News Today

    As with coffee or alcohol, the way each person processes medication is unique. One person's perfect dose may be another person's deadly overdose.

    Comment?

  13. Celsion Corporation (CLSN) Receives Daily Media Sentiment Rating of 0.19Read the original story w/Photo

    Thursday Sep 14 | Daily Political

    News stories about Celsion Corporation have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time.

    Comment?

  14. DoD Grant to Advance Possible Metastatic Breast Cancer Treatment From Lab to Patients in Record TimeRead the original story w/Photo

    Thursday Sep 14 | Newswise

    A team of Houston Methodist researchers and clinicians received two grants totaling over $15.7 million from the Department of Defense to accelerate a possible treatment for metastatic breast cancer. Metastases to the lungs and liver are responsible for the vast majority of breast cancer deaths every year in the United States, yet there is no cure.

    Comment?

  15. DoD grant to advance possible metastatic breast cancer treatment in record timeRead the original story w/Photo

    Tuesday Sep 12 | EurekAlert!

    A team of Houston Methodist researchers and clinicians received two grants totaling over $15.7 million from the Department of Defense to accelerate a possible treatment for metastatic breast cancer. Metastases to the lungs and liver are responsible for the vast majority of breast cancer deaths every year in the United States, yet there is no cure.

    Comment?

  16. Fennec Announces Preliminary Results of SIOPEL 6 Study on PEDMARKa ...Read the original story

    Wednesday Sep 13 | Customer Interaction Solutions

    Fennec Announces Preliminary Results of SIOPEL 6 Study on PEDMARK to be Presented at the 49TH Congress of the International Society of Pediatric Oncology 2017 Meeting Fennec Announces Preliminary Results of SIOPEL 6 Study on PEDMARK to be Presented at the 49TH Congress of the International Society of Pediatric Oncology 2017 Meeting SIOPEL 6 shows that the addition of sodium thiosulfate significantly reduces the incidence of cisplatin-induced hearing loss without any evidence of tumor protection Among the first 94 evaluable patients, hearing loss occurred in 29/44=65.9% under Cisplatin Arm and in 19/50=38.0% under Cis+STS Arm, corresponding to a relative risk of 0.57 RESEARCH TRIANGLE PARK, N.C., Sept.

    Comment?

  17. Fennec Announces Preliminary Results of SIOPEL 6 Study on PEDMARK...Read the original story w/Photo

    Wednesday Sep 13 | GlobeNewswire

    Fennec Announces Preliminary Results of SIOPEL 6 Study on PEDMARKa to be Presented at the 49TH Congress of the International Society of Pediatric Oncology 2017 Meeting SIOPEL 6 shows that the addition of sodium thiosulfate significantly reduces the incidence of cisplatin-induced hearing loss without any evidence of tumor protection Among the first 94 evaluable patients, hearing loss occurred in 29/44=65.9% under Cisplatin Arm and in 19/50=38.0% under Cis+STS Arm, corresponding to a relative risk of 0.57 RESEARCH TRIANGLE PARK, N.C., Sept.

    Comment?

  18. Eos Biosciences Announces Issuance of U.S. Patent for Novel Oncology TheranosticRead the original story

    Wednesday Sep 13 | Customer Interaction Solutions

    Eos Biosciences, Inc. , a bio-targeted nanomedicines company developing a novel nanoparticle drug delivery platform, with a proprietary oncology pipeline, announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,757,386, which covers Eos Biosciences' theranostic product Eos-002, a HER3-targeted Eosome for the treatment and imaging of solid tumors.

    Comment?

  19. PharmaMar Release: New Positive Data On PM1183 Sees A Response Rate...Read the original story

    Tuesday Sep 12 | BioSpace

    The abstract #1529 ' Activity of lurbinectedin as single agent and in combination in patients with advanced small cell lung cancer ' shows an objective response rate of 36% when PM1183 is used as a single agent. The results become of special relevance if it is taken into account that microcitic lung cancer is the most aggressive type of lung cancer for which only one treatment exists, topotecan, approved more than 15 years ago in advanced and relapsed illness.

    Comment?

  20. New data on PM1183 sees a response rate of 36 percent as single agent in patients with SCLCRead the original story w/Photo

    Monday Sep 11 | EurekAlert!

    Madrid, September 12th, 2017.- PharmaMar has presented today during the European Society for Medical Oncology congress , held in Madrid, positive results of PM1183 in a cohort of 36 patients as monotherapy in patients with advanced and relapsed small-cell lung cancer . The abstract #1529 'Activity of lurbinectedin as single agent and in combination in patients with advanced small cell lung cancer ' shows an objective response rate of 36% when PM1183 is used as a single agent.

    Comment?